Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 09/27 10:00:23 pm
119.22 USD   +1.22%
04:19p JOHNSON & JOHNS : Two US companies eye Seagate land in Batu Kawan
09/26 JOHNSON & JOHNS : FDA Approves STELARA® (Ustekinumab) for Treatment ..
09/26 JOHNSON & JOHNS : Research finds talc doesn't cause cancer; juries d..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Recalls Nearly 54,000 Packages Of Imodium Antidiarrhea Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2012 | 07:41pm CEST
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) has recalled nearly 54,000 packages of Imodium Multi-Symptom Relief antidiarrhea pills due to a potential packaging defect.

J&J's McNeil consumer-health division said Thursday an internal review revealed the potential for a limited number of blister-packaging units--which contain the pills--to have dents with a small pinhole or tear.

J&J said the voluntary recall was being conducted at the wholesale level only, and not from consumers or store shelves. J&J said there were no safety concerns or adverse events associated with the recall.

The company said consumers may continue to use the product if there is no hole or tear in the blister unit. An Imodium caplet taken from a damaged blister unit, however, may not provide the full benefit of the product as intended. J&J advised patients not to take the product if the blister unit is torn or open.

J&J said it has made improvements to the packaging line to try to prevent the issue from happening again.

J&J has manufactured more than 2.75 million packages of Imodium Multi-Symptom Relief Caplets over the past five months, and except for the one lot being recalled, the product remains on store shelves, said spokeswoman Barbara Montresor.

J&J's McNeil unit has issued a series of recalls for popular over-the-counter medicines like Tylenol over the past two and a half years for various quality lapses. The recalls have cost the company hundreds of millions of dollars in lost sales and costs to fix the manufacturing problems.

More information about the recall can be found at the Imodium product website: http://www.imodium.com/page.jhtml?id=imodium/include/news.inc.

J&J shares rose 0.2% to $63.81 in recent trading.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
04:19p JOHNSON & JOHNSON : Two US companies eye Seagate land in Batu Kawan
09/26 JOHNSON & JOHNSON : FDA Approves STELARA® (Ustekinumab) for Treatment of Adults ..
09/26 JOHNSON & JOHNSON : Research finds talc doesn't cause cancer; juries disagree
09/25 JOHNSON & JOHNSON : The Philadelphia Inquirer Kellie Patrick Gates column
09/25 JOHNSON & JOHNSON : Dennis W. Weaver
09/24 PFIZER INC. : vs. Johnson & Johnson
09/23 JOHNSON & JOHNSON : Michael Ullmann Appointed to Princeton Area Community Founda..
09/23 JOHNSON & JOHNSON : Parametric Portfolio Associates buys $772,134,349 stake in J..
09/22 JOHNSON & JOHNSON : U.S. FDA Approves INVOKAMET® XR (Canagliflozin / Metformin H..
09/21 GLOBAL BABY BATH PRODUCT MARKET 2016 : Mamas and Papas, Johnson and Johnson, Fis..
More news
Sector news : Pharmaceuticals - NEC
08:49aDJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03:12p Amgen's Kyprolis Clarion Call Falls On Deaf Ears
12:09p My 85 Stock Portfolio Evaluation Of Want To Buy Prices And Yields For Purchas..
09/26 FDA OKs Johnson & Johnson's Stelara for Crohn's disease
09/26 MY 4% DIVIDEND YIELD PORTFOLIO : Q3'16 Summary And Plans For Q4
09/26 GILEAD : Ways To Unlock Shareholder Value
Advertisement
Financials ($)
Sales 2016 72 075 M
EBIT 2016 21 925 M
Net income 2016 16 508 M
Finance 2016 14 428 M
Yield 2016 2,66%
P/E ratio 2016 20,06
P/E ratio 2017 17,67
EV / Sales 2016 4,27x
EV / Sales 2017 4,00x
Capitalization 322 232 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 127 $
Spread / Average Target 7,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON14.66%322 232
ROCHE HOLDING LTD.-11.18%215 081
NOVARTIS AG-8.70%211 231
PFIZER INC.4.21%204 049
MERCK & CO., INC.17.66%171 858
GLAXOSMITHKLINE PLC20.39%103 357
More Results